Synergistic Orthobiologics: Combining HA with Platelet-Rich Plasma (PRP)
In 2026, the "Gold Standard" for moderate osteoarthritis is moving toward Combination Therapy, specifically the co-injection of Hyaluronic Acid and Platelet-Rich Plasma (PRP).
Clinical trials in early 2026 have demonstrated that while HA provides the mechanical "cushioning" and lubrication, the growth factors in PRP address the underlying inflammatory environment. This synergistic approach has shown superior results in reducing VAS (Visual Analog Scale) pain scores compared to either treatment alone. By reducing humoral and cellular immune responses while simultaneously promoting angiogenesis (the formation of new blood vessels), this dual-action therapy not only masks symptoms but may also help preserve the existing histological parameters of the articular cartilage.